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• Tenascin is an extracellular matrix protein with highly 
regulated expression and uncertain functions. It is prominently 
expressed during musculoskeletal embryogenesis. The pattern 
of distribution of tenascin in healthy adult musculoskeletal 
tissues is spatially and temporally restricted. It can be only de- 
tected in a small amount in the muscle-tendon junctions, ten- 
dons, perichondrium, periosteum, endosteum, the superficial 
layer of articular cartilage and the subintimal connective tis- 
sue ofsynovium. Elevated tenascin expression is found in in- 
flammatory, degenerative and neoplastic lesions of the mus- 
culoskeletal system. The peculiar pattern of tenascin expres- 
sion suggests it may play a role in the regulation of cell be- 
havior at the interfaces bet\veen different elements of the mus- 
culoskeletal system and in various pathological processes, in 
particular those involving attachment and/or detachment of 
cells from the extracellular matrix and their proliferation and 
collagenase secretion. 
INTRODUCTION 
• Tenascin (Tn) has also been referred to as hexabrachion 
(1), cytotactin (2), glioma mesenchymal extracellular matrix 
protein (3), Jl glycoprotein (4) and nryotendinous antigen (5). 
Tn is a large oligomeric, modular glycoprotein of extracellu- 
lar matrix consisting of six similar subunits joined together at 
N-terminal domain by disulphide bonds in the central region. 
This six-armed structure, called hexabrachion, is probably 
subjected to a rapid intracellular assembly. The N-terminal 
domain is connected to two coiled triplexes, each of which is 
formed by a combination of heptad repeats of three subunits. 
The extended subunit is completed by a series of epidermal 
growth factor (EGF)-like repeats, a series of fibronectin type 
III repeats and a carboxyl (C)-terminal fibrinogen-like domain 
(6, 7) (Fig. 1,2). 
Different Tn isoforms are generated by alternative splicing of 
pre-mRNA. In normal cells this alternative splicing is con- 
trolled by extracellular pH (8). These isoforms have different 
numbers of fibronectin type III repeats and thus different mo- 
lecular sizes (9-11). There are two main isoforms of human Tn: 
the small Tn isoform has eight fibronectin type III repeats and 
a molecular weight of approximately 190 kD, whereas the large 
Tn isoform contains seven extra fibronectin type III repeats 
inserted between domains five and six and has a molecular 
weight of approximately 290 kD (Fig.3). They may have dif- 
ferential functions, with the small variant being preferentially 
bound to purified fibronectin and to fibronectin-containing 
extracellular matrix in fibroblast cultures (Fig.3). The major 
fibronectin binding site is located in the third fibronectin type 
III repeat and with an additional weak binding site, probably 
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Figure 1. The large 290kDtcnascin-C isnform is shown 
schematically with all the six arms of the hexabrachion 
being extended away from the N-terminal central do- 
main. 
Figure 2. A schematic presentation of the extended arm 
of the large 290 kD ten ascin-C isoform. The heptad re- 
peat region depicted consists of a triplex formed by the 
heptad domain of three subunits. 
  
FigureS. Panel A. Double indirect immunof- 
luorescence staining of cultured human em- 
bryonal fibroblasts for tenascin with a mono- 
clonal antibody (a) and for fibronectin with a 
rabbit antiserum (b). Note that tenascin im- 
munoreactivity only partially codistributes 
with that of fibronectin fibers, being particu- 
larly abundant in more coarse fibers. Panel 
B  ̂ Fluorography ofS
3i
-methionine metaboli- 
cally labelled cultured human embryonal 
skin fibroblasts analysed for production of te- 
nascin polypeptides into the culture medium. 
Immunoprecipitation with monoclonal anti- 
bodies to tenascin shows in one of the human 
skin fibroblast strains both the 190 kD and 
290 kD tenascin polypeptide (lane 1), while 
in another strain only the 190 kD tenascin 
polypeptide is precipitated (lane 2). Both cell 
strains assemble tenascin into extracellular 
matrix similarly.  
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in domains 6-8 being exposed in the small 190 kD Tn isoform. 
The structural and functional sites of human Tn are as follows 
(12) 
Signal peptide: 1-22 
Heptad repeats: 119-125, 126-132, 133-139 
EGF-Iike repeats: 174-185, 186-216, 217-247, 248-279, 
     280-310, 311-341, 342-372, 373-403, 404-434, 435-465, 
466-496, 497-527, 528-558, 559-589, 590-620 
Fibronectintype IH-like repeats: 621-708,709-801,802- 
891, 892-983, 984-1071, 1072-1162, 1163-1253, 1254- 
1344, 1345-1435, 1436-1526, 1527-1617, 1618-1708, 
     1709-1797, 1798-1885, 1886-1973 
Alternatively spliced repeats: 1072-1162, 1163-1253, 
1254-1344,1345-1435, 1436-1526, 1527-1617, 1618-1708 
Fibrinogen-like domain: 1981-2190 
Potential N-linked glycosylation sites: 38, 166, 184, 327, 
788,1018,1034, 1079,1093,1119,1184, 1210,1261,1275, 
1301, 1366, 1392, 1445, 1455, 1485, 1534, 1809, 2161 
Arginine-aspartic acid-glycine (RGD) site: 877-879 
Among Tn polypeptide family, Tn-C is the prototype discov- 
ered, with C indicating cytotactin. Three analogues to Tn-C 
have been recently discovered. First, Tn-R was originally de- 
scribed under the name of restrictin (13). It consists of the same 
type of domains as Tn-C while its preparations contain trim- 
ers, dimers and monomers instead of hexamers (14). Tn-R is 
found exclusively in the nervous system and is most prominent 
during development (15,16). Second, Tn-X was originally re- 
ported as a partial sequence encoded by gene XB in human 
major histocompatibility complex class III region. Its mRNA 
expression is most prominent in fetal muscle and testis (IT- 
19). Tn-Y is a newly described member of Tn family and is 
produced by differentiated fibroblasts of muscle connective tis- 
sue (20). The emphasis of this review is on Tn-C, and the name 
Tn, without a letter, will be used only for Tn-C.  
DISTRIBUTION, FUNCTION, PRODUCTION AND 
REGULATION OF TENASCIN 
• During embryonic development, Tn has a spatially and 
temporally restricted expression. It is strikingly expressed at 
the sites of epithelial-mesenchymal interactions, indicating that 
Tn may be induced by actively growing epithelium (21-23). Tn 
expression is also conspicuous in developing dense connective 
tissue (24). 
In adult tissues, Tn is absent or much more restricted than in 
developing tissues. It can be detected at the epithelial-stromal 
interfaces, although sometimes faint stromal Tn is noted too 
(25-30). Tn is absent in some adult connective tissues but is 
prominently detected during certain stages of differentiation 
and tissue remodeling associated with developmental and 
pathological changes (31). In healing wound, Tn is present in 
the matrix of the granulation tissue and under the proliferat- 
ing and migrating epidermal layer. After healing, the expres- 
sion of Tn returns to normal (32, 33). 
Because of its extensive expression in some malignant lesions 
and its absence in many normal adult tissues, Tn expression 
was once thought to be a marker of malignant growth. How- 
ever, recent research has shown that Tn is also present in some 
normal tissues and benign lesions even though significant Tn 
enhancement has been shown in most carcinomas (26, 34). 
Although elevated serum Tn levels were found in most carci- 
noma patients (35), the highest level of serum Tn have been 
noted in patients with acute sepsis. It has been postulated that 
Tn is induced as an acute phase protein in liver through the 
action of inflammatory mediators (36). 
The functions of tenascin are still largely unknown. Originally 
tenascin has been described to be a potent hemagglutinin (1). 
Tn possesses both adhesive cell-binding and matrix protein- 
binding domains and anti-adhesive domains. Tn has an anti- 
adhesive or adhesion-modulating effect through interference 
with the action of fibronectin (Fig. 3) and Tn may thus play a 
role in reducing cell adhesion to fibronectin (37, 38). The ca- 
pacity of Tn to inhibit fibronectin dependent adhesion and 
migration may depend on its ability to block the binding sites 
on fibronectin or its receptors. However, recent studies show 
that interaction of Tn with its cell surface receptor, annexin 
II, is able to induce loss of focal adhesion (39). Together with 
fibronectin, Tn induces fibroblasts to secrete collagenase, which 
suggests that Tn has an effect on morphogenetic events and 
tissue remodeling involving proteolysis (40). Tn appears to 
stimulate cell growth and thus exhibits a mitogenic property 
on fibroblasts (41). Tn is thought to be a modulator of matrix- 
cell interactions and to be involved in various differentiation 
events (42). Tn has also been shown to have an immunosup- 
pressive activity by inhibiting T-cell activation (43, 44). 
RDG sequence in fibronectin type III repeats may be respon- 
sible for Tn-mediated cell attachment (9). Many cells attached 
to Tn remain rounded and do not flatten and spread as it is seen 
on fibronectin coated substrate (45). Several cellular receptors 
that spread on Tn and mediate Tn action have been suggested 
and include integrins a2(3l, a8(il, a9(il, aVp3, and aVp"6 
(46), contactin (47) and annexin II (48). Another binding site 
in Tn molecule was found to be the fibrinogen-like C-termi- 
nal knob. It has been claimed that only the binding of the fi- 
brinogen-like C-terminal knob of Tn to a2 (i 1 integrin may play 
a biologically significant role based on the fact that there are 
species variation of RGD sequence and cryptic location of some 
RGD sites (49). Recent studies show that the interaction of 
integrins a9(31 or aVp3 with the third fibronectin type III re- 
peat of Tn can directly stimulate cell proliferation (50) 
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Many earlier studies demonstrated that Tn was present in 
mesenchyme, but not in epithelium, at sites of mesenchymal- 
epithelial interactions. It has once been suggested that epithe- 
lial cells do not synthesize Tn, whereas fibroblasts do. This 
assumption needs to be revised since an in situ hybridization 
study has showed that epithelial cells are also able to produce 
Tn (51). In cell culture, both amnion epithelial cells and bron- 
chial epithelial cells synthesize Tn and assemble it to extra- 
cellular matrix (52, 53). Given the appropriate environment 
and stimuli, almost all cells can produce Tn although such an 
ability has not been described, at least not yet, for blood cells 
and muscle cells. 
The highly regulated pattern of Tn expression suggests that its 
synthesis may be modulated, at least in part by mechanical 
forces and a series of soluble factors such as hormones and 
cytokines. The structure of the 5'-region of the human tenas- 
cin gene contains several potential binding sites for transcrip- 
tion factors, which indicates that complex mechanisms con- 
trol the transcriptional regulation of Tn gene. Transforming 
growth factor-p was the first one shown to upregulate Tn ex- 
pression (54). To date, a long list of growth factors and cytoki- 
nes have been found to upregulate Tn expression (Table 1). 
Elevated Tn expression has been shown to be induced by me- 
chanical force exerted on fibroblasts cultured in restrained 
collagen gel. while Tn synthesis was decreased in a floating, 
contracting gel (64). The results suggest that mechanical force 
may have an important role in the regulation of Tn expression 
during developmental, regenerative and morphogenetic pro- 
Table 1. Regulation oftenascin expression 
cesses. Thus, mechanical force exerted on tissues is translated 
to an altered protein pattern of the extracellular matrix. This 
can also partly explain the mechanism of the generation of bone 
(spicules) along the line of force acting on the bone, which 
would help to remodel the bone according to mechanical de- 
mands, according to the law of Wolff. 
Tn can be readily catabolized by extracellular matrix protein- 
ases. Only matrix metalloproteinase (MMP)-7, also known as 
matrilysin, can degrade small Tn isoform while MMP-7, MMP- 
2 and MMP-3 are all involved in the degradation of the larger 
Tn isoform. Cathepsin G and leukocyte elastase can also di- 
gest Tn (65, 66). Glucocorticoids are shown to downregulate 
Tn expression in bone marrow stroma (61), tumor stroma (62) 
and healing wound (63). 
TENASCIN EXPRESSION IN DEVELOPING 
CARTILAGE AND BONE 
During cartilage embryogenesis, Tn is produced by chondro- 
genic cells in the condensing mesenchyme of cartilage anlagen 
while it is absent from the surrounding mesenchyme. Tn ex- 
pression decreases with chondrocyte differentiation and is 
undetectable in mature and hypertrophic cartilage (24). In day 
7 chick embryo, Tn was found in newly formed vertebral car- 
tilage with a homogenous distribution. Tn could not be detected 
in mature cartilage but persisted in surrounding perichondrium 
(67). It is commonly hold that in early stages of chondrocyte 
development. Tn is only expressed by poorly differentiated 
chondrocytes at epiphyseal ends while fully-differentiated 
chondrocytes do not produce Tn (68). 
During articular cartilage development, Tn was first detected 
in cell condensation region of day 4 chick embryo limb bud. 
With development, Tn was only present in the articular cap of 
the models. Tn persisted in articular cartilage throughout post- 
natal life but decreased with age. There was a tissue-specific 
distribution of Tn isoforms around articular cap. The shortest 
Tn isoform (Tn 190) was almost exclusively detected in the 
cartilage, whereas the peripheral articular cartilage, the region 
near fibrocartilage, fibrocartilage and the outer layer of peri- 
chondrium contained both Tn 190 and Tn 200. The largest Tn 
isoform (Tn 230) was only detected in the articular cartilage 
associated tissues, ligaments and meniscus. Tn was absent from 
growth plate cartilage undergoing endochondral ossification 
and was barely detectable in the secondary ossification center 
within the articular cap (69). 
During the healing of cartilage injury, Tn was undetectable in 
the initially formed blastema, i.e. in the primitive granulation 
tissue formed after injury, consisting mainly of hematoma, 
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tissue. With differentiation of chondroblasts and osteoblasts, 
Tn was detected in the matrix surrounding these cells. After 
the regenerating cartilage matured, Tn staining disappeared 
(70). 
In vitro study showed that addition of Tn to substrate, in which 
the chondrocytes were cultured, stimulated chondrogenesis 
(24). When anti-tenascin antibody was added to culture me- 
dia, chondrogenesis was inhibited (71). The promotion of 
chondrogenesis is thought to be through the effect of Tn on cell 
shape, i.e. by the anti-adhesive effect of Tn, which counteracts 
fibronectin-mediated adhesion, since round morphology is 
necessary for the maintenance of chondrocyte phenotype (72). 
During endochondral bone formation, Tn is detected around 
the osteogenic cells invading the cartilage model. During mem- 
branous bone formation, Tn is first present in condensing 
mesenchyme and later present around the spicules of forming 
bone. Tn is absent from mineralized bone matrix (24). In mem- 
branous bone of growing rat skull, Tn was present in imma- 
ture bone matrix and was most prominent in areas where the 
periosteum and perichondrium were thickened such as sites of 
some muscle attachment (73). 
In human fetal long bone, Tn was present in a clearly defined 
and characteristic beaded pattern, i.e. granular distribution 
along type III collagen. At the sites of active bone formation, 
Tn expression on collagen type III fibers was particularly 
strong. In the middle region adjacent to the basophilic corti- 
cal bone, staining of Tn on collagen type III was also conspicu- 
ous. In the mature bone of adult mandible, there was no stain- 
ing of Tn on collagen type III fiber. However, in adult man- 
dible bone with dysplastic lesion, Tn was present with a dif- 
fuse and irregular pattern in the soft fibrous tissue adjacent to 
the site of early ossification. Different Tn expression may rep- 
resent different stages of osteogenic differentiation. The regu- 
lar, characteristically beaded pattern of Tn distribution on type 
III collagen implicates that bone tissue is developing toward 
maturity (74). 
Alkaline phosphatase (AP) is thought to be involved in matrix 
mineralization by catalyzing the hydrolysis of phosphate ester 
bonds at alkaline pH in hard connective tissues. In growing 
membranous bone, Tn and AP were detected in periosteum and 
perichondrium. Activity of AP was confined to the inner layer 
of periosteum while Tn expression extended to more superficial 
layer. The wider distribution of Tn suggests that it may func- 
tion at an earlier stage of hard tissue formation than AP (75). 
Although Tn is undeteclable in mature mineralized bone ma- 
trix, osteoblasts express Tn both in vivo and in vitro. Cultured 
osteoblasts from chicken, human and rat synthesize exclusively 
the largest Tn isoform, whereas fibroblast cultures from peri- 
ostea of chicken calvariae synthesized approximately equal 
amounts of all three isoforms. The results suggest that progres- 
sive osteoblast differentiation from multipotential precursor cell 
correlates with the loss of Tn diversity. The additional fibronec- 
tin type III repeats in the large Tn isoform may play a role in 
the maintenance of round shape of osteoblasts by its antiadhe- 
sive effect (76, 77). 
TENASCIN EXPRESSION IN ARTHRITIC SYNOVIUM 
AND CARTILAGE 
The histopathologic features of arthritis include synovial lin- 
ing cell hyperplasia, mononuclear cell infiltration, vascular 
changes and fibrosis (78, 79). These changes result in degra- 
dation of extracellular matrix in the synovial tissue itself and 
in the articular cartilage covered by an abnormal extension of 
the synovial tissue known as pannus (from Latin, a piece of 
cloth). Local production of a variety of matrix molecules is of 
vital importance for the return of tissue to normal after injury. 
In normal synovium, Tn is often found around blood vessels 
and just beneath the synovial lining cell layer, but is rarely 
detected in the normal synovial lining layer itself (Table 2). 
Extensive staining of Tn was seen in synovium specimens from 
patients with osteoarthritis. Tn was diffusely distributed in the 
subintimal connective tissue with the expression being particu- 
larly strong in areas of sclerosis and fibrosis. Tn was also promi- 
nently expressed in perivascular regions, and in the synovial 
lining layer (82,83) (Table 2, Fig.4a). 
In rheumatoid arthritis, strong and diffuse Tn expression was 
detected in the synovial lining layer, in particular among the 
fibroblast-like type B synovial cells, in perivascular areas and 
in areas of fibrosis. In inflammatory cell infiltration with 
densely packed lymphocytes, Tn expression was described to 
be either weak (83) or increased (84) (Table 2, Fig.4b). 
In situ hybridization showed that inRNA
Tn
 was detected at a 
low level in normal synovium in synovial lining and in perivas- 
cular regions. A striking increase of Tn expression was seen 
in synovium from patients with arthritis. In arthritic synovium, 
there was an increase in the number of cells expressing mRNA
Tn 
and an increase in the level of mRNA
T
° expressed in individual 
cells. Interleukin-1 induced cultured synovial fibroblasts to 
produce Tn (84). 
The localization of Tn in normal and arthritic synovium sug- 
gests that it may have a regulatory effect on the interaction 
between synovial lining and sublining tissue and between blood 
vessels and perivascular connective tissue matrix. Due to its 
effects on immune function and cell adhesion, Tn may have a 
role in the pathogenesis of arthritis. Locally produced cytokines 
may modulate the expression and thus effects of Tn.   
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Table 2. Tenascin expression in normal and pathologically altered synovial membrane, hyaline cartilage, ligament, and tendon 
Tissue              Normal Pathological                                                                    Refs 
Synovium          Small amount underneath the synovial In osteoarthritis (OA) and rheumatoid arthritis (RA),       80-84 
lining cell layer increased expression spreadingto synovial lining 
 
layer and deep subsynovial tissue zone 
Articular           Small amount in the surface zone In OA and RA, extensive distribution with a diffuse      81,83,85 
cartilage                                                                          pattern in the surface zone and pericellular pattern 
in the deep layers                                          
Ligament          Small amount at the sites of attachment Intense expression in ligaments with injury or                  86, 87   
to bone (enthesis) degeneration 
Tendon             Weak expression in organized, fibrous Strong expression associated with some round cells             88 
                    region of tendon matrix in disorganized fibrocartilaginous tissue                                 .- 
  
 
Figure 4. Tenascin staining of synovial membrane from osteoarthritis (a) and rheumatoid arthritis (b). Strong lenascin staining 
can be seen in the synovial lining cell layer and in the sublining connective tissue. Note also the prominent staining of the 
perivascular connective tissue matrix. '
  
In normal human cartilage, Tn is present in small amount and 
usually confined to superficial zone. Sometimes Tn expression 
extends focally to the matrix surrounding chondrocytes of upper 
mid zone. Normal cartilage explant treated with interleukin-1 
expressed Tn in almost all of the pericellular areas of all car- 
tilage layers, but not in the matrix at sites distant from chondro- 
cytes (81,85).  
In the articular cartilage from patients with osteoarthritis, Tn 
was found mainly in the superficial layer, but also in the tran- 
sitional and deep zones of the undecalcified hyaline articular 
cartilage. In the extracellular matrix near surface, Tn expres- 
sion was diffuse and irregular, whereas in the deep layer of 
cartilage, it was expressed in a pericellular pattern. In the ar- 
eas showing severe pathological changes such as vertical fis- 
sure, superficial cartilage loss and cell clustering, Tn expres- 
sion was particularly strong and extended to both the interter- 
ritorial and pericellular regions of the deep zone, sometimes 
even to subchondral bone undergoing osteoid remodeling. In 
the articular cartilage from patients with rheumatoid arthritis,   
88 
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Tn was seen in all layers of the cartilage and in the juxtasub- 
chondral (i.e. in the bone just below the subchondral bone plate) 
zones of bone in a pericellular pattern. Tn expression was 
strong also in pannus, adjacent residual hyaline articular car- 
tilage and reparative fibrocartilage (81, 83, 85). 
The mechanism of Tn accumulation in arthritic cartilage re- 
mains to be elucidated. Strong expression in surface zones 
suggests passive absorption from synovial fluid. Nevertheless, 
its pericellular location in deeper layer of articular cartilage 
indicates that production by chondrocytes may contribute to 
increased local levels. Increased local Tn production in arthritic 
cartilage is likely to be a part of reparative and inflammatory 
response in injured joints. Elevated Tn levels may antagonize 
the adverse effects of increased fibronectin to chondrocyte 
metabolism, i.e. fibronectin-mediated inhibition of synthesis 
of the cartilage matrix, and fibronectin mediated inhibition of 
chondrocyte migration to the site of lesions. 
TENASCIN EXPRESSION IN TUMORS OF 
THE MUSCULOSKELETAL SYSTEM 
• Tn and proliferating cell nuclear antigen (PCNA) were 
investigated in benign and malignant cartilage tumors. Tn was 
barely detectable in the fully differentiated cartilage of enchon- 
droma and low grade chondrosarcoma. In the high grade 
chondrosarcoma, Tn was strongly expressed at the periphery 
of tumor lobules and matrix. Intense staining of PCNA was 
found in the spindle-shaped cells of high-grade chondrosar- 
coma. The distribution of PCNA-positive cells always corre- 
sponded to the regions with Tn reactivity. Surprisingly, Tn and 
PCNA were present in all chondroblastoma specimens, indi- 
eating that there is a relatively high proliferative activity in 
chondroblastoma (89). These data suggest that Tn plays a role 
in promoting tumor cell proliferation and its synthesis seems 
to be the result of tumor development. However, further stud- 
ies are needed before determination of the significance and 
prognostic value of Tn in benign and malignant cartilage tu- 
mors can be done. 
Synovial sarcoma is a soft tissue tumor with characteristic bi- 
phasic structure consisting of epithelial and spindle mesenchy- 
mal cells. Strong Tn expression was found in the mesenchyme 
immediately around epithelial cells. Tn was barely detectable 
in the monophasic tumors and in the mesenchymal tissue dis- 
tant from epithelial elements in the biphasic tumors. This pe- 
culiar pattern of Tn distribution suggests that it is involved in 
neoplastic epithelial-mesenchymal interactions (90) (Table 1). 
TENASCIN EXPRESSION IN OTHER CONDITIONS 
• In human yellow ligament, Tn was present in the matrix 
around fibroblasts of entheses, particularly in transitional re- 
gion between the cartilage and ligament. The appearance of Tn 
in human yellow ligament varied with age and was frequent in 
spinal disease with ossification (86). Tn was sparsely distrib- 
uted in normal anterior cruciate ligament (ACL), but strongly 
expressed in ruptured ligament with a time-restricted pattern. 
The data suggest that Tn is an important factor during healing 
of ACL (87). In human skeletal muscle, Tn was found in a short 
segment of the muscle spindle fibers, in the equatorial region 
where the sensory nerve endings are found, and in the outer 
layers of the spindle capsule. Tn was also found in the neuro- 
muscular junctions of the extrafusal fibers. The close spatial 
Table 3. Tenascin expression in tumors of the musculoskeletal system 
Type of tumor Tenascin expression                                                                                          Refs 
Enchondroma Rarely detected                                                                                          89 
Chondroblastoma Commonly detected                                                                                                      89 
Chondrosarcoma Grade I:   weak staining in tumor lobules, interlobular septa and fibrous capsule         89 
                            Grade II: increased staining at the margins of the lobules        
Grade III: intensive staining throughout the matrix 
        Synovial sarcoma                   Strong staining in mesenchymal tissue around epithelial elements and weak               90 
                staining in mesenchymal tissue distant from the epithelial elements and in 
                    monophasic tumors 
Osteomacutis Strongly expressed                                                                                                    91 
Rhabdomyosarcoma 
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relationship between Tn and nerve endings implicates that Tn 
is of functional importance in adult nerve-muscle contacts in 
human skeletal muscle (92). Tn production may become stimu- 
lated by the regenerative process of skeletal muscle and remains 
upregulated until the muscle undergoes successful regeneration 
(93). In normal human tendons, Tn was associated with orga- 
nized, fibrous regions of the tendon matrix, while in the degen- 
erative tendons, Tn was strongly associated with some round 
cells in disorganized fibrocartilagenous regions (88). 
CONCLUSION 
• Tenasein expression is associated with developmental, 
regenerative, degenerative, inflammatory and neoplastic events 
of musculoskeletal system, and almost always present at the 
sites with active tissue turnover (see Table 2,3). 
ACKNOWLEDGEMENTS 
• We wish to thank Ville Waris for the preparation of the 
manuscript. 
1. Erickson HP, Inglesias JL. A six-armed oligomer isolated 
from cell surface fibronectin preparations. Nature 1984; 
311:267-269 
2.     Grumet M, Hoffman S, Crossin KL, Edelman GM. 
Cytotactin, an extracellular matrix protein of neural and 
non-neural tissues that mediates glia-neuron interaction. 
Proc Natl Acad Sci USA 1985; 82: 8075-8079 
3. Bourdon MA, Wickstrand CT, Furthmayr H, Mattews TJ, 
Bigner DD. Human glioma-mesenchymal extracellular 
matrix antigen defined by monoclonal antibody. Cancer 
Res 1983; 43: 2796-2805 
4.     Kruse J, Keilhauer G, Faissner A, Timpl R Schachner M. 
The Jl glycoprotein - a novel nervous system cell adhesion 
molecule of L2/HNK-1 family. Nature 1985; 316:146-148 
5. Chiquet M, Famrough DM. Chick myotendinous antigen. 
I. A monoclonal antibody as a marker for tendon and 
muscle morphogenesis. /Cell Biol 1984; 98: 1926-1936 
6.     Johns FS, Hoffman S, Cunningham BA, Edelman GM. A 
detailed structural model of cytotactin: protein homolo- 
gies, alternative RNA splicing, and binding regions. Proc 
Natl Acad Sci USA 1989; 86: 1905-1909 
7.     Erickson HP. Evolution of the tenascin family - implica- 
tions for function of the C-terminal fibrinogen-like do- 
main. Persp Dev Neumhiol 1994; 2: 9-19 
8.     Borsi L, Allemanni G, Gaggero B, Zardi L. Extracellular 
pH controls pre-mRNA alternative splicing of tenascin-C 
in normal, but not in malignantly transformed, cells. M 
JCancer 1996; 66: 632-635 
9.     Gulcher JR, Nies DE, Morton LS, Stefansson K. An alter- 
natively spliced region of the human hexabrachion con- 
tains a repeat of potential N-glycosylation sites. Proc Natl 
AcadSci USA 1989; 86: 1588-1592 
10.   Siri A, Carnemolla B, Saginati M, Leprini A, Casari G, 
Baralle F et al. Human tenascin: primary structure, pre- 
mRNA splicing patterns and localization of the epitopes 
recognized by two monoclonal antibodies. Nucleic Acids 
Res 1991; 19:525-531 
11.   Sriramarao P, Bourdon MA. A novel tenascin type III 
repeat is part of a complex of tenascin mRNA alternative 
splices. Nucleic Acids Res 1993; 21: 163-168 
12.   Nies DE, Hemesath TJ, Kirn JH, Gulcher JR, Stefansson 
K. The complete cDNA sequence of human hexabrachion 
(tenascin). J Biol Chem 1991; 266: 2818-2823 
13. Rathjen FG, Wolff JM, Chiquet-Ehrismann R. Restrictin: 
A chick neural extracellular matrix protein involved in cell 
attachment co-purifies with the cell recognition molecules 
Fll. Development 1991; 113: 151-164 
14.   Nornberg U, Wille H, Wolff JM, Frank R, Rathjen FG. 
The chicken neural extracellular matrix molecule restric- 
tin: similarity with EGF-, fibronectin type III-, and fibrino- 
gen-like motifs. Neuron 1992; 8: 849-863 
15.   Bartsch U, Pesheva P, Raff M, Schachner M. Expression 
ofjanusin (Jl-160/180) in the retina and optic nerve of the 
developing and adult mouse. Glia 1993; 9: 57-69 
16.   Wintergest ES, Fuss B, Bartsch U. Localization of janusin 
mRNA in the central nervous system of the developing arid 
adult mouse. Eur JNeurosci 1993; 5: 299-310 
17.   Morel Y, Bristow J, Gitelman SE, Miller WL. Transcript 
encoded on the opposite strand of human steroid 21-hy- 
droxylase /complement component of C4 gene locus. Proc 
Natl AcadSci USA 1989; 86: 6582-658 
18.   Gitelman SE, Bristow J, Miller WL. Mechanism and con- 
sequences of the duplication of human C4/P450c21/ gene 
X locus. Molec Cell Biol 1992; 12: 2124-2134   
90 
 
Biomed Rev 6,1996 
Tenascin expression in musculoskeletal system 
  
19.   Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL. 
Tenascin-X: A novel extracellular matrix protein encoded 
by the human XB gene overlapping P450c2 IB../ Cell Biol 
1993; 122: 265-278 
20.   Hagios C, Koch M, Spring J, Chiquet M, Chiquet- 
Ehrismann R. Tenascin-Y: A protein of novel domain 
structure is secreted by differentiated fibroblasts of muscle 
connective tissue. J Cell Biol 1996; 134: 1499-1512 
21. Chiquet-Ehrismann R, Mackie E J, Pearson C A, Sakakura 
T. Tenascin: an extracellular matrix protein involved in 
tissue interactions during fetal development and oncoge- 
nesis. Cell 1986; 47: 131-139 
22.   Aufderheide E, Chiquet-Ehrismann R, Ekblom P. Epithe- 
lial-mesenchymal interactions in the developing kidney 
lead to expression of tenascin in the mesenchyme. J Cell 
Biol 1987;105:599-608  
23. Ekblom P, Aufderheide E. Stimulation of tenascin expres- 
sion in mesenchyme by epithelial-mesenchymal interac- 
tions. MJDevBiol 1989; 33: 71-79 
24.   Mackie EJ, Thesleff I, Chiquet-Ehrismann R. Tenascin is 
associated with chondrogenic and osteogenic differentia- 
          tion in vivo and promotes chondrogenesis in vitro. J Cell 
Biol 1987: 105: 2569-2579 
25.   Howeedy AA, Virtanen I, Laitinen L, Gould NS, 
Koukoulis GK, Gould VE. Differential distribution of 
tenascin in the normal, hyperplastic and neoplastic breast. 
         Lab Invest 1990: 63: 798-806     
26.   Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, 
        Howeedy AA, Virtanen I. Tenascin in normal, reactive, 
        hyperplastic, and neoplastic tissue: biologic and patho- 
        logic implications. Hum Pathol 1991; 22: 636-643 
27.   Yamada S, Ichida T, Matsuda Y, Miyazaki Y, Hatano T, 
        Hata K etal. Tenascin expression in human chronic liver 
        disease and in hepatocellular carcinoma. Liver 1992; 12: 
         10-16     . 
28.   Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, 
        Walther PJ, Bigner DD et al. Tenascin expression in pro- 
        static hyperplasia, intraepithelial neoplasia, and carci- 
        noma. Hum Pathol 1993; 24: 982-989      
29.   Ocklind G, Talts J, Fa'ssler R, Mattson A, Ekblom P. 
       Expression of tenascin in developing and adult mouse                 
lymphoid organs. JHistochem Cytochem 1993; 41:1163- 
1169 
30.   Soini Y, Paakko P, Nuorva K, Kamel D, Linnala A, 
Virtanen I et al. Tenascin immunoreactivity in lung tu- 
mors. Am J Clin Pathol 1993; 100: 145-150 
31.   Schalkwijk J, van Vlijmen, Oosterling B, Perret C, 
Koopman R, van den Born T et al. Tenascin expression in 
hyperproliferative skin diseases. BrJDermatol 1991; 124: 
13-20 
32.   Mackie EJ, Halfter W, Liverani D. Induction of tenascin 
in healing wounds. J Cell Biol 1988; 107: 2757-2767 
33.   LuomanenM, Virtanen I. Distribution of tenascin in heal- 
ing incision, excision and laserwounds. J Oral PatholMed 
1993; 22: 41-45 
34.   Natali PG, Nicotra MR, Bigotti A, Botti C, Castellani P, 
Risso AM et al. Comparative analysis of the expression of 
the extracellular matrix protein tenascin in normal human 
fetal, adult and tumor tissues. Int. J Cancer 1991; 47: 811- 
816 
3 5. Riedl S, Bodenmuler H, Hinz U, Holle R, Moller P, Schlag 
P et al. Significance of tenascin serum level as tumor 
marker in primary colorectal carcinoma. IntJ Cancer 
1995; 64:65-69 
36.   Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. 
Tenascin-C in serum: a questionable tumor marker. IntJ 
Cancer 1995; 61: 443-449 
37.   Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, 
Chiquet M. Tenascin interferes with fibronectin action. 
Cell 1988; 53: 383-390 
38.   Sage EH, Bornstein P. Extracellular proteins that mo- 
dulate cell matrix interaction. J Biol Chem 1991; 266: 
14831-14834 
39.   Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogen- 
esis, cell migration, and loss of focal adhesions induced by 
tenascin-C interacting with its cell surface receptor, anne- 
xin II. Mol Biol Cell 1996; 7: 883-892 
40.   Tremble P, Chiquet-Ehrismann R, Werb Z. The extracel- 
lular matrix ligands fibronectin and tenascin collaborate 
in regulating collagenase gene expression in fibroblast. 
Mol Biol Cell 1994; 5: 439-453 
41.   Engel J. EGF-like domains in extracellular matrix pro- 
teins: localized signals for growth and differentiation. 
   FEES Lett 1989; 251: 1-7 
  
91 
Biomed Rev 6,1996 
Li, Konttinen, Xu, Imai, Matucci-Cerinic, Ceponis, Santavirta, and Virtanen 
  
42.   End P, Panayotou G, Entwistle A, Waterfield MD, 
Chiquet M. Tenascin: a modulator of cell growth. Eur J 
Biochem 1992; 209: 1041-1051 
43.   Riiegg CR, Chiquet-EhrismannR, Alkan SS. Tenascin, an 
extracellular matrix protein, exerts immunomodulatory 
activities. Proc NatlAcadSci USA 1989; 86: 7437-7441 
44.   Hemesath TJ, Marton LS, Stefansson K. Inhibition of T 
cell activation by the extracellular matrix protein tenascin. 
Jlmmunol 1994; 152: 5199-5207 
45.   Lotz MM, Burdsal CA, Erickson HP, McClay DR. Cell 
adhesion to fibronectin and tenascin: qualitative measure- 
ments of initial binding and subsequent strengthening 
response. J Cell Biol 1989; 109: 1795-1805 
46.   Prieto AL, Edelman GM, Crossin KL. Multiple integrins 
mediate cell attachment to cytotaclin / tenascin. Proc Natl 
AcadSci USA 1993; 90: 10154-10158 
47.   Zisch AH, D'Alessandri L, Ranscht B, Falchetto R, 
Winterhalter KH, Vaughan L. Neuronal cell adhesion 
           molecule contactin /Fll binds to tenascin via its immu- 
noglobulin-like domains. J Cell Biol 1992; 119: 203-213 
48.   Chung CY, Erickson HP. Cell surface annexin II is high 
      affinity receptor for the alternatively spliced segment of 
  
     Tenascin-C. J Cell Biol 1994, 126: 539-548 
49.   Joshi P, Chung CY, Aukhil I, Erickson HP. Endothelial 
cells adhere to the RGD domain and the fibrinogen-like 
       terminal knob of tenascin. / Cell Sci 1993; 106: 389-400 
50.   Yokosaki Y, Monis H, Chen J, Shepherd D. Differential 
 
    effects of the integrins ct9pl, av|33,and av|}6 on cell pro- 
     liferative responses to tenascin. J Biol Chem 1996; 271: 
     24144-24150 
51. Lightner VA, Marks JR, McCachren SS. Epithelial cells are 
an important source of tenascin in normal and malignant 
human breast tissue. Exp Cell Res 1994; 210: 177-184 
52.   Linnala A, Balza E, Zardi L, Virtanen I. Human amnion 
epithelial cells assemble tenascins and three fibronectin 
isoforms in the extracellular matrix. FEES Lett 1993; 317: 
      74-78 
53. Linnala A, Kinnula V, Laitinen LA, Lehto VP, Virtanen I. 
Transforming growth factor-P regulates the expression of 
fibronectin and tenascin in BEAS 2B human bronchial epi- 
thelial cells. Am JRespir CellMolBiol 1995; 13: 578-585 
54.   Pearson CA, Pearson D, Shibahara S, Hofsteenge J, 
Chiquet-Ehrismann R. Tenascin: cDNA cloning and in- 
duction by TGF-J3. EMBO J 1988; 7: 2977-2981 
5 5. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. 
Tenascin expression in the mouse: in situ localization and 
induction in vitro by bFGF../ Cell Sci 1993; 104: 69-76 
56.   Sakai T, Ohta M, Furukawa Y, Saga Y, Aizawa S, 
Kawakatsu H et al. Tenascin-C induction by tlie diffusible 
factor epidermal growth factor in stromal-epithelial inter- 
s     actions. J Cell Physiol 1995; 165: 18-29 
57.   Yavin E, Gabai A, Gil S. Nerve growth factor mediates 
monosialoganglioside-induced release of fibronectin and 
Jl /tenascinfrom C6 glioma cells. JNeurochem 1991; 56: 
105-112 
58.   Mackie EJ, Scott-Burden T, Hahn AWA, Kern F, 
Bernhardt J, Regenass S et al. Expression of tenascin by 
vascular smooth muscle cells. Alterations in hypertensive 
rats and stimulation by angiotensin II. Am JPathol 1992; 
141: 377-388 
59.   Rettig WJ, Erickson HP, Albino AP, Garin-Chesa P. In- 
duction of human tenascin(neuronectin) by growth factors 
and cytokines: cell type-specific signals and signalling 
pathways. J Cell Sci 1994; 107: 487-497 
60.   Umbhauer M, Riou JF, Spring J, Smith JC, Boucaut JC. 
Expression of tenascin mRNA in mesoderm during Xeno- 
pus laevis embryogenesis: the potential role of mesoderm 
patterning in tenascin regionalization. Development 1992; 
116: 147-157 
61. Ekblom M, Fassler R, Tomasini-Johansson B, Nilsson K, 
Ekblom P. Downregulation of tenascin expression by glu- 
cocorticoids in bone marrow stromal cells and in fibro- 
blasts. JCellBiol 1993; 123:1037-1045 
62.   Talts TF, Weller A, Timpl R, Ekblom M, Ekblom P. Regu- 
lation of mesenchymal extracellular matrix protein syn- 
thesis by transforming growth factor-beta and glucocorti- 
coids in tumor stroma. J Cell Sci 1995; 108: 2153-2162 
63. Fassler R, Sasaki T, Timpl R, Chu ML, Werner S. Differ- 
ential regulation of fibulin, tenascin-C and nidogen ex- 
pression during wound healing of normal and glucocorti- 
coid-treated mice. Exp Cell Res 1996; 222: 111-116 
64. Chiquet-Ehrismann R, Tannheimer M, Koch M, Branner 
A, Spring J, Martin D et al. Tenascin-C expression by   
92 
Biomed Rev 6,1996 
Tenascin expression in musculoskeletal system 
  
fibroblast is elevated in stressed collagen gel. / Cell Biol 
1994; 127: 2093-2101 
65.   Imai K, Kusakabe M, Sakatura T, Nakanishi I, Okada Y. 
Susceptibility of tenascin to degradation by matrix me- 
talloproteinases and serine proteinases. FEES Lett 1994; 
352: 216-218 
66.   Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi 
L. Different susceptibility of small and large human tenas- 
cin-C isoform to degradation by matrix metalloproteina- 
ses. JBiol Chem 1995; 270: 8650-8654 
67.   Crossin KL, Hoffman S, Grumet M, Thiery JP, Edelman 
GM. Site-restricted expression of cytotactin during devel- 
opment of the chick embryo. J Cell Biol 1986; 102: 1917- 
1930 
68.   Prieto AL, Jones FS, Cunningham BA, Crossin KL, 
Edelman GM. Localization during development of alter- 
natively spliced forms of cytotactin mRNA by in situ hy- 
bridization. J Cell Biol 1990; 111: 685-698 
69.   Pacifici M, Iwamoto M, Golden EB, Leatherman JL, Lee 
YS, Chuong CM. Tenascin is associated with articular 
cartilage development. Dev Dyn 1993; 198: 123-134 
70.   Chuong CM, Chen HM. Enhanced expression of neural 
cell adhesion molecules and tenascin (cytotactin) during 
wound healing. AmJPathol 1991; 138: 427-440 
71.   Brooks JD, Tanzer ML. Tenascin plays a role in early 
cartilage formation [abstract]. MolBiol Cell 1992; 3:230 
72.   Mackie EJ. Tenascin in connective tissue development 
andpathogenesis. Persp Dev Neurobiol 1994; 2: 125-132 
73. Thesleff I, Kantomaa T, Mackie EJ, Chiquet-Ehrismann 
R. Imnumohistochemical localization of the matrix glyco- 
protein tenascin in the skull of the growing rat. Archs Oral 
Biol 1988; 33: 383-390 
74.   Cater DH, Sloan P, Aaron JE. Immunolocalization of 
        collagen type I and III, tenascin, and fibronectin in intra-           
membranous bone. JHistochem Cytochem 1991; 39:599- 
         606 
75.   Vakeva L, Mackie EJ, Kantomaa T, Thesleff I. Compari- 
        son of me distribution of patterns of tenascin and alkaline 
        phosphatase in developing teeth, cartilage, and bone of 
         rats and mice. AnatRec 1990; 228: 69-76 
76.   Mackie EJ, Tucker RP. Tenascin in bone morphogenesis: 
expression by osteoblasts and cell type-specific expression 
of splice variants. / Cell Sci 1992; 103: 765-771 
77.   Mackie EJ, Tucker RP. Expression of tenascin by bone 
cells: synthesis by osteoblasts and regulation by transform- 
ing growth factor-p [abstract]. Calc Tissue Int 1992; 50: 
13  
78.   KonttinenYT, Reitamo S, Ranki A, Hayry P, Kankaanpaa 
U, Wagelius O. Characterization of the immunocompetent 
cells of rheumatoid synovium from tissue sections and 
eluates. Arthritis Rheum 1981; 24: 71-79 
79.   Konttinen YT, Nykanen P, Nordstrom D, Saari H, 
Sandelin J, Santavirta S et al. DNA synthesis in prolyl 4- 
hydroxylase positive fibroblasts in situ in synovial tissue. 
An autoradiography-immunoperoxidase double labeling 
study. JRheitmatol 1989; 16: 339-349 
80.   Cutolo M, Balza E, Sun MZ, Ponassi M. Evidence of te- 
nascin in normal synovial tissue: variation in osteoarthritis 
[abstract]. BrJRheumatol 1992; 2(Suppl): 201 
81. Cutolo M, Salter DM. Tenascin and arthritis. BrJRheumatol 
1994; 33: 197-198 
82.   Cutolo M, Picasso M, Ponassi M, Sun MZ, Balza E. Te- 
nascin and flbronectin distribution in human normal and 
pathological synovium. JRheumatol 1992; 19:1439-1447 
83.   Salter DM. Tenascin is increased in cartilage and syno- 
vium from arthritic knees. BrJRheumatol 1993; 32: 780- 
786 
84.   McCachren SS, Lightner VA. Expression of human 
tenascin in synovitis and its regulation by interleukin-1. 
Arthritis Rheum 1992; 35: 1185-1195 
85. Chevalier X, Groult N, Larget-Piet B, Zardi L, Hornebeck 
W. Tenascin distribution in articular cartilage from normal 
subjects and from patients with osteoarhtritis and rheuma- 
toid arthritis. Arthritis Rheum 1994; 37: 1013-1022 
86. Fujii Y, Yoshida H. Sakou T. Immunohistochemical stud- 
ies on tenascin in human yellow ligament. In vivo 1993; 
7: 143-146  
87. Neuroth M. Expression of tenascin, laminin and flbronec- 
tin following traumatic rupture of the anterior cruciate 
ligament. Z Orthop Ihre Grenzgeb 1993; 131: 168-172   
93 
Biomed Rev 6,1996 
94 Li, Konttinen, Xu, Imai, Matucci-Cerinic, Ceponis, Santavirta, and Virtanen 
88.   Riley GP, Harrall RL, CawstonTE, Hazleman BL, Mackie 
EJ. Tenascin-C and human tendon degeneration. Am J 
Pathol 1996; 149: 933-943 
89.   Hasegawa T, Seki K, Yang P, Hirose T, Hizawa K, Wada 
T et al. Differentiation and proliferative activity in benign 
and malignant cartilage tumors of bone. Hum Pathol 
1995; 26: 838-845 
90.   Guarino M, Christensen L. Immunohistochemical analy- 
sis of extracellular matrix components in synovial sar- 
coma. J Pathol 1994; 172: 279-286 
91.   Oikarinen A, Tuomi ML, Kallionen M, Sandberg M, 
Vaananen K. A study of bone formation in osteoma cutis 
employing biochemical, histochemical and in situ hybrid- 
ization techniques. ActaDerm Venereal 1992; 72:172-174 
92.   Pedrosa-Domellof F, Virtanen I, Thornell LE. Tenascin 
is present in human muscle spindles and neuromuscular 
junctions. Neurosci Lett 1995; 198: 173-176 
93. Settles DL,Cihak RA, Erickson HP. Tenascin-C expres- 
sion in dystrophin-related muscular dystrophy. Muscle 
Nerve 1996; 19: 147-154 
  Received28 October 1996 
 
Accepted 30 November 1996 
For correspondence: 
  Dr Yrjo T. Konttinen 
Department of Anatomy 
University of Helsinki 
PO Box 9 (Silta\>uorenpenger 20A) 
FIN-00014 Helsinki 
                               Finland 
     Tel: 358(9) 1918477 










Biomed Rev 6,1996 
